Cover Image
市場調查報告書

Advair(氣喘):市場預測與分析

Advair (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316073
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Advair(氣喘):市場預測與分析 Advair (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 53 Pages
簡介

Advair是由GSK所開發的丙酸Fluticasone及salmeterol xinafoate的FDC(固定劑量複方藥物)。丙酸Fluticasone是具有強力消炎作用的合成皮質類固醇。Fluticasone可與糖皮質激素受體以高度親和性結合,抑制氣喘相關媒介物(組織胺,類花生酸,白三烯,細胞激素等)的分泌。具有比budenoside3倍、二丙酸氯地米松活性代謝物2倍的效能。同時salmeterol xinafoate也是高度選擇性LABA(長效型β2刺激藥)。

本報告提供氣喘治療藥之一──Advair的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,Advair的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定公開的相關報告書

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療指南,臨床診療及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭評估

第6章 Advair(丙酸Fluticasone/salmeterol xinafoate)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Advair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate. Salmeterol xinafoate is a highly selective LABA.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Advair including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Advair for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Advair performance
  • Obtain sales forecast for Advair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Advair (fluticasone propionate/salmeterol xinafoate)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Advair
  • Table 8: Efficacy - Advair Diskus Versus Its Individual Components
  • Table 9: Advair, Frequency of Drug-Related Adverse Events
  • Table 10: Advair SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Advair, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top